These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 27563870)
1. Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist. Ahn YH; Lee JY; Park HD; Kim TH; Park MC; Choi G; Kim S Molecules; 2016 Aug; 21(9):. PubMed ID: 27563870 [TBL] [Abstract][Full Text] [Related]
2. Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y Lei Y; Zhang B; Liu D; Zhao J; Dai X; Gao J; Mao Q; Feng Y; Zhao J; Lin F; Duan Y; Zhang Y; Bao Z; Yang Y; Mou Y; Wang S J Med Chem; 2020 Dec; 63(24):15752-15772. PubMed ID: 33307675 [TBL] [Abstract][Full Text] [Related]
3. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064 [TBL] [Abstract][Full Text] [Related]
4. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861 [TBL] [Abstract][Full Text] [Related]
5. Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane. Rabani V; Montange D; Meneveau N; Davani S Platelets; 2018 Nov; 29(7):709-715. PubMed ID: 29020490 [TBL] [Abstract][Full Text] [Related]
6. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Ferri N; Corsini A; Bellosta S Drugs; 2013 Oct; 73(15):1681-709. PubMed ID: 24114622 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents. Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677 [TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists. Chao H; Turdi H; Herpin TF; Roberge JY; Liu Y; Schnur DM; Poss MA; Rehfuss R; Hua J; Wu Q; Price LA; Abell LM; Schumacher WA; Bostwick JS; Steinbacher TE; Stewart AB; Ogletree ML; Huang CS; Chang M; Cacace AM; Arcuri MJ; Celani D; Wexler RR; Lawrence RM J Med Chem; 2013 Feb; 56(4):1704-14. PubMed ID: 23368907 [TBL] [Abstract][Full Text] [Related]
10. Antithrombotic P2Y Baqi Y; Müller CE Drug Discov Today; 2019 Jan; 24(1):325-333. PubMed ID: 30291899 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents. Yang W; Wang Y; Lai A; Qiao JX; Wang TC; Hua J; Price LA; Shen H; Chen XQ; Wong P; Crain E; Watson C; Huang CS; Seiffert DA; Rehfuss R; Wexler RR; Lam PY J Med Chem; 2014 Jul; 57(14):6150-64. PubMed ID: 24931384 [TBL] [Abstract][Full Text] [Related]
13. Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y Liu X; Gao ZG; Wu Y; Stevens RC; Jacobson KA; Zhao S Sci Rep; 2018 May; 8(1):8084. PubMed ID: 29795391 [TBL] [Abstract][Full Text] [Related]
14. Role of P2Y receptor subtypes in platelet-derived microparticle generation. Kahner BN; Dorsam RT; Kunapuli SP Front Biosci; 2008 Jan; 13():433-9. PubMed ID: 17981558 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of P2Y receptor subtypes - an update. von Kügelgen I Purinergic Signal; 2024 Apr; 20(2):99-108. PubMed ID: 37697211 [TBL] [Abstract][Full Text] [Related]